Septerna: The SEP-479 Readout Could Unlock Further Upside

Septerna, Inc. (SEPT) is expected to release data from its SEP-479 clinical trial in the coming weeks, which could drive further upside for the stock.

The trial is testing a potential treatment for a rare genetic disorder.